These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Relative effectiveness and cost-effectiveness of methods of androgen suppression in the treatment of advanced prostate cancer. Seidenfeld J; Samson DJ; Aronson N; Albertson PC; Bayoumi AM; Bennett C; Brown A; Garber A; Gere M; Hasselblad V; Wilt T; Ziegler K Evid Rep Technol Assess (Summ); 1999 May; (4):i-x, 1-246, I1-36, passim. PubMed ID: 11098244 [TBL] [Abstract][Full Text] [Related]
4. Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE). Kawakami J; Cowan JE; Elkin EP; Latini DM; DuChane J; Carroll PR; Cancer; 2006 Apr; 106(8):1708-14. PubMed ID: 16544313 [TBL] [Abstract][Full Text] [Related]
5. Hormonal therapy for locally advanced prostate cancer. Einstein AB NCI Monogr; 1988; (7):171-4. PubMed ID: 3050536 [TBL] [Abstract][Full Text] [Related]
6. The nonsteroidal effects of diethylstilbestrol: the rationale for androgen deprivation therapy without estrogen deprivation in the treatment of prostate cancer. Scherr DS; Pitts WR J Urol; 2003 Nov; 170(5):1703-8. PubMed ID: 14532759 [TBL] [Abstract][Full Text] [Related]
8. Hormonal therapy for stage D cancer of the prostate. Gudziak MR; Smith AY West J Med; 1994 Apr; 160(4):351-9. PubMed ID: 8023485 [TBL] [Abstract][Full Text] [Related]
9. Complete androgen blockade for the treatment of prostate cancer. Labrie F; Dupont A; Belanger A Important Adv Oncol; 1985; ():193-217. PubMed ID: 3916740 [No Abstract] [Full Text] [Related]
10. Hormonal management of advanced adenocarcinoma of the prostate. Miles BJ Henry Ford Hosp Med J; 1989; 37(1):16-8. PubMed ID: 2670839 [No Abstract] [Full Text] [Related]
11. Cost-effectiveness of androgen suppression therapies in advanced prostate cancer. Bayoumi AM; Brown AD; Garber AM J Natl Cancer Inst; 2000 Nov; 92(21):1731-9. PubMed ID: 11058616 [TBL] [Abstract][Full Text] [Related]
12. Hormone therapy of prostatic bone metastases. Huben RP Adv Exp Med Biol; 1992; 324():305-16. PubMed ID: 1492625 [TBL] [Abstract][Full Text] [Related]
13. Hormonal ablation therapy for metastatic prostatic carcinoma: a review. Leewansangtong S; Soontrapa S J Med Assoc Thai; 1999 Feb; 82(2):192-205. PubMed ID: 10087729 [TBL] [Abstract][Full Text] [Related]
14. Controversies surrounding androgen deprivation for prostate cancer. Patterson SG; Balducci L; Pow-Sang JM Cancer Control; 2002; 9(4):315-25. PubMed ID: 12228757 [TBL] [Abstract][Full Text] [Related]
15. A critical review of the concept of total androgen ablation in the treatment of prostate cancer. Schulze H; Isaacs JT; Coffey DS Prog Clin Biol Res; 1987; 243A():1-19. PubMed ID: 3309968 [No Abstract] [Full Text] [Related]
16. Medical versus surgical androgen suppression therapy for prostate cancer: a 10-year longitudinal cost study. Mariani AJ; Glover M; Arita S J Urol; 2001 Jan; 165(1):104-7. PubMed ID: 11125375 [TBL] [Abstract][Full Text] [Related]
17. Overview of current status of total androgen deprivation in metastasized prostate cancer. Debruyne FM; Witjes WP Eur Urol; 1993; 24 Suppl 2():67-71. PubMed ID: 8262129 [TBL] [Abstract][Full Text] [Related]